NEU 5.98% $20.20 neuren pharmaceuticals limited

For anyone who is interested, it's a live webcast, Wednesday US...

  1. 356 Posts.
    lightbulb Created with Sketch. 107
    For anyone who is interested, it's a live webcast, Wednesday US time. Interesting that Trofinetide is mentioned, second only to pimavanserin.

    GLTAH
    LO

    SAN DIEGO--(BUSINESS WIRE)--Aug. 12, 2020--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.

    The conference will be held virtually. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through September 19, 2020.

    About ACADIA Pharmaceuticals

    ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA’s development efforts are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.20
Change
1.140(5.98%)
Mkt cap ! $2.579B
Open High Low Value Volume
$19.58 $20.52 $19.47 $9.631M 477.6K

Buyers (Bids)

No. Vol. Price($)
1 181 $20.19
 

Sellers (Offers)

Price($) Vol. No.
$20.24 245 1
View Market Depth
Last trade - 16.10pm 14/05/2024 (20 minute delay) ?
Last
$20.21
  Change
1.140 ( 5.70 %)
Open High Low Volume
$19.56 $20.51 $19.53 123739
Last updated 15.59pm 14/05/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.